Research
Tafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specializing in the development of treatments for relieving and preventing acute and chronic pain (inflammatory, postoperative, neuropathic) without adverse effects, is pleased to announce that its teams are today moving to a new site with dedicated research and support […]
Lire la suiteAziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 protein Dr Moqrich is Research Director at the IBDM laboratory (part of the CNRS, the French National Center for Scientific Research) and cofounder of Tafalgie Therapeutics. Th award recognizes the major discoveries he and his team have made, […]
Lire la suite